Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$454.74 USD

454.74
1,490,141

+5.80 (1.29%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $454.82 +0.08 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Zacks Equity Research

The Zacks Analyst Blog Highlights: AMETEK, Thermo Fisher Scientific, IQVIA, Lowe's Companies and Alexion Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: AMETEK, Thermo Fisher Scientific, IQVIA, Lowe's Companies and Alexion Pharmaceuticals

Sweta Killa headshot

5 Most-Loved S&P 500 Stocks on Wall Street

by Sweta Killa

Given the bullishness and record-high market, we have screened for five S&P 500 stocks that are most loved by the brokerage firms.

Zacks Equity Research

Penumbra's (PEN) Q3 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Penumbra (PEN) witnessed strong growth across all geographies and product lines in Q3.

Zacks Equity Research

Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

DexCom (DXCM) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Nevro (NVRO) Q3 Loss Narrower Than Expected, Revenues Up Y/Y

by Zacks Equity Research

Nevro (NVRO) launches the Senza Omnia SCS System commercially in the United States in Q3.

Zacks Equity Research

DexCom (DXCM) Earnings and Revenues Beat Estimates in Q3

by Zacks Equity Research

DexCom's (DXCM) Q3 earnings benefit from higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook. However, contraction in gross margin remains a woe.

Zacks Equity Research

Glaukos (GKOS) Q3 Loss Narrower Than Expected, '19 View Up

by Zacks Equity Research

Glaukos' (GKOS) Q3 revenues surge year over year. Also, the company raises 2019 revenue guidance.

Zacks Equity Research

LHC Group (LHCG) Q3 Earnings Surpass Estimates, Revenues Lag

by Zacks Equity Research

LHC Group (LHCG) third-quarter results benefit from home health and hospice admissions and higher revenues.

Zacks Equity Research

National Vision's (EYE) Q3 Earnings Top Estimates, View Raised

by Zacks Equity Research

National Vision's (EYE) third-quarter performance reflects strong growth in core business segments.

Zacks Equity Research

Option Care Health (BIOS) Q3 Earnings Meet, Revenues Top

by Zacks Equity Research

Albeit Option Care Health (BIOS) is yet to reap material benefits from its merger-related synergies, the reporting of a positive gross margin in third-quarter results is encouraging for investors.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Beats on Q3 Earnings, Ups '19 View

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) gains from solid segmental contributions in Q3.

Zacks Equity Research

Globus Medical (GMED) Q3 Earnings Meet Mark, Revenue View Up

by Zacks Equity Research

Globus Medical (GMED) reports robust top-line numbers for the third quarter on segmental strength.

Zacks Equity Research

Hologic's (HOLX) Q4 Earnings Meet, Revenues Top Estimates

by Zacks Equity Research

Hologic (HOLX) exhibits robust fourth-quarter growth fueled by strong segmental performance.

Zacks Equity Research

Cardinal Health (CAH) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Cardinal Health (CAH) Q1 results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.

Zacks Equity Research

AmerisourceBergen (ABC) Q4 Earnings & Revenues Beat Estimates

by Zacks Equity Research

AmerisourceBergen's (ABC) Q4 earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.

Zacks Equity Research

Insulet (PODD) Beats on Q3 Earnings, Ups '19 Revenue View

by Zacks Equity Research

Insulet's (PODD) year-over-year improvement in Q3 revenues on the solid uptake of Omnipod system both in the United States and across international markets looks promising.

Zacks Equity Research

OPKO Health (OPK) Q3 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

OPKO Health (OPK) third-quarter results benefit from higher Product revenues and RAYALDEE prescription growth.

Zacks Equity Research

CVS Health (CVS) Beats on Q3 Earnings, Raises '19 EPS Guidance

by Zacks Equity Research

CVS Health's (CVS) strong year-over-year growth in the top line is aided by a robust performance at the Pharmacy Services segment.

Zacks Equity Research

Phibro's (PAHC) Q1 Earnings & Revenues Fall Y/Y, Margins Down

by Zacks Equity Research

Phibro (PAHC) exhibits a dismal first-quarter performance on a decline in revenues at core business segments.

Zacks Equity Research

HMS Holdings (HMSY) Q3 Earnings Top Estimates, Revenues Miss

by Zacks Equity Research

HMS Holdings' (HMSY) Q3 earnings benefit from higher revenues at Analytical Services unit and strong 2019 outlook.

Zacks Equity Research

Avanos (AVNS) Earnings and Revenues Miss Estimates in Q3

by Zacks Equity Research

Avanos (AVNS) third-quarter results benefit from higher revenues and strong segmental performance.

Zacks Equity Research

Zacks.com featured highlights include: SYNNEX, Thermo Fisher Scientific, Allstate, Intel and Target

by Zacks Equity Research

Zacks.com featured highlights include: SYNNEX, Thermo Fisher Scientific, Allstate, Intel and Target

Zacks Equity Research

Inogen's (INGN) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Softness in domestic and international business-to-business revenues impact Inogen's (INGN) Q3 results.

Zacks Equity Research

DaVita (DVA) Earnings and Revenues Beat Estimates in Q3

by Zacks Equity Research

DaVita (DVA) raises guidance for 2019 following impressive Q3 results.